You are viewing the site in preview mode

Skip to content


  • Poster presentation
  • Open Access

Optimizing engineered TCR T cell therapy for synovial sarcoma

  • 1,
  • 2,
  • 3,
  • 2,
  • 4,
  • 3,
  • 4,
  • 1,
  • 5,
  • 5,
  • 2,
  • 1,
  • 4,
  • 3 and
  • 2
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P159

  • Published:


  • Melanoma
  • Sarcoma
  • Fludarabine
  • Synovial Sarcoma
  • Manufacturing Method

Relapsed or metastatic synovial sarcoma remains a significant unmet medical need. NY-ESO-1 is an attractive target for sarcoma, since it is expressed in approximately 70% of synovial sarcomas but not on vital tissues. We generated NY-ESOc259, a human-derived affinity-enhanced T-cell receptor (TCR) that recognizes the NY-ESO-1– derived SLLMWITQC peptide in complex with HLA-A*02. Adoptive transfer of autologous T cells expressing NY-ESOc259 was clinically tested in patients with metastatic synovial cell sarcoma and melanoma whose tumor expressed NY-ESO-1 protein at an intensity of ≥2+ and in 50% of cells by immunohistochemistry; infusion followed preconditioning with fludarabine and cyclophosphamide, and systemic IL-2 support was given[1]. We subsequently initiated a study in relapsed/metastatic synovial sarcoma, with an updated T cell manufacturing method utilizing anti-CD3/28 paramagnetic microbeads for simultaneous activation and co-stimulation of T cells, and genetic modification with a lentivector (NCT01343043). No IL-2 support was given. Outcomes of this study were recently presented[2]; clinical data demonstrate safety, objective clinical responses in 50% of patients, and improved and durable engineered T cell persistence. This study has been extended to include two additional cohorts to evaluate the removal of fludarabine on tumor responses (Cohort 3) and to evaluate responses in patients who have antigen positive tumor below the current ≥2+ and 50% threshold (Cohort 2).

To better understand the lineage and functional characteristics of the persisting engineered T cells, as well as to understand the role of the starting material and manufacturing method in modifying the T cell phenotype and its fate once in vivo, we performed multiparameter flow analysis. Baseline and post infusion PBMCs, as well as manufactured product, were analyzed to evaluate memory and exhaustion markers (e.g. CD45RA, CCR7, PD-1), polyfunctionality/cytotoxicity markers (e.g. IFN-γ and Granzyme B), and costimulatory markers (e.g. OX40, ICOS, CD28). TCR expression was measured by pentamer. Hierarchical cluster analysis was applied to identify trends of expression of surface markers and their correlation with final cell product profile, persistence and clinical response. An update of Cohort 1 safety, efficacy and correlative biomarker analyses, and a status update on Cohorts 2 and 3 will be presented.

Trial registration identifier NCT01343043.

Authors’ Affiliations

Memorial Sloan Kettering Cancer Center, New York, NY, USA
National Cancer Institute, Bethesda, MD, USA
Adaptimmune, Abingdon,, United Kingdom
Adaptimmune, Philadelphia, PA, USA
Immunecarta Services, Montreal, USA


  1. Robbins PF, et al: A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response. Clinical Cancer Research. 2015, 21 (5): 1019-27.PubMedView ArticleGoogle Scholar
  2. Merchant Melinda, et al: Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. American Society of Clinical Oncology. 2015, Chicago, IllinoisGoogle Scholar


© D'Angelo et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.